Palbociclib provides new option in breast cancer

Palbociclib (Ibrance) is licensed for use in combination with endocrine therapy to treat hormone receptor positive HER2-negative locally advanced or metastatic breast cancer.

by Lisa Lytle
Palbociclib (Ibrance) is given once daily orally together with endocrine therapy | SCIENCE PHOTO LIBRARY
Palbociclib (Ibrance) is given once daily orally together with endocrine therapy | SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package